Uterine Cancer Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Uterine Cancer Information Center has current, evidence-based information for you. Get the facts about uterine cancer prevention, early detection, treatment, and survivorship, and stay up to date with ongoing uterine cancer research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Uterine Cancer Community is the leading Social Media Application for Uterine Cancer patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the... OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine
Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition... Weighing the Risks
An unhealthy weight, whether it’s too little weight or too much, can in fact have dramatic effects on health.
By Barbara A. Goff, MD, President, Society of Gynecologic Oncology and Foundation... Understanding Osteonecrosis of the Jaw
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse...
Uterine Cancer Management
Actress, producer, and advocate Fran Drescher launches a movement created to change... Jack & Jill Late Stage Cancer Foundation
Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the... Moving Bodies, Changing Lives
Moving On Aerobics helps women regain joy of movement and physical fitness after...
Uterine Cancer Clinical Trials
GOG0209 – A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
GOG0238 – A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
GOG0248 – A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC # 683864, IND # 61010) or the Combination of Hormonal Therapy Plus Temsirolimus in Women with Advanced, Persistent, or Recurrent Endometrial Carcinoma